Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Paul J Yazaki"'
Autor:
Ekaterina Mikhaylova, Jamison Brooks, Darren M. Zuro, Farouk Nouizi, Maciej Kujawski, Srideshikan Sargur Madabushi, Jinyi Qi, Mengxi Zhang, Junie Chea, Erasmus K. Poku, Nicole Bowles, Jeffrey Y. C. Wong, John E. Shively, Paul J Yazaki, Gultekin Gulsen, Simon R. Cherry, Susanta K. Hui
Publikováno v:
IEEE Access, Vol 7, Pp 143207-143216 (2019)
Molecular imaging is becoming essential for precision targeted radiation therapy, yet progress is hindered from a lack of integrated imaging and treatment systems. We report the development of a prototype positron emission tomography (PET) scanner in
Externí odkaz:
https://doaj.org/article/2c0540aaf4bd44a48e2b7ed5b73c5749
Autor:
Richard T Frank, Marissa Edmiston, Stephen E Kendall, Joseph Najbauer, Chia-Wei Cheung, Thewodros Kassa, Marianne Z Metz, Seung U Kim, Carlotta A Glackin, Anna M Wu, Paul J Yazaki, Karen S Aboody
Publikováno v:
PLoS ONE, Vol 4, Iss 12, p e8314 (2009)
BACKGROUND: Recombinant monoclonal antibodies have emerged as important tools for cancer therapy. Despite the promise shown by antibody-based therapies, the large molecular size of antibodies limits their ability to efficiently penetrate solid tumors
Externí odkaz:
https://doaj.org/article/3159f93b5aa04d759d7b2560ec324484
Autor:
Lindsay Williams, Lin Li, Paul J. Yazaki, Patty Wong, Teresa Hong, Erasmus K. Poku, Susanta Hui, Hemendra Ghimire, John E. Shively, Maciej Kujawski
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background The potent immune effects of interleukin‐2 (IL‐2) for cancer therapy can be increased by genetic fusion of IL‐2 to the Fc domain of an antibody (IL‐2‐Fc) or tumor targeted by genetic fusion to a whole antibody known as a
Externí odkaz:
https://doaj.org/article/5d59608a2bfc41f3848415e9d3c06ce0
Autor:
Jeffrey Y.C. Wong, David M. Yamauchi, Vikram Adhikarla, Jennifer Simpson, Paul H. Frankel, Yuman Fong, Kurt A. Melstrom, Yi-jen Chen, Behrooz D. Salehian, Yanghee Woo, Savita V. Dandapani, David M. Colcher, Erasmus K. Poku, Paul J. Yazaki, Anna M. Wu, John E. Shively
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 38:26-37
Autor:
Susanta K. Hui, Paul J. Yazaki, John E. Shively, David Colcher, Anthony S. Stein, Jeffrey Y.C. Wong, Daniel A. Vallera, Joseph Rosenthal, Justin Molnar, Todd Ebner, Aaron Miller, Nicole Bowles, Kofi Poku, Junie Chea, Indu Nair, Paresh Vishwasrao, Marvin Orellana, Liliana Echavarria Parra, James Sanchez, Bijender Kumar, Darren Zuro, Jamison Brooks, Sargur Madabushi Srideshikan
Supplementary methods and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b396894fb3df95612d145e68cc1be5
https://doi.org/10.1158/1078-0432.22472484
https://doi.org/10.1158/1078-0432.22472484
Autor:
Susanta K. Hui, Paul J. Yazaki, John E. Shively, David Colcher, Anthony S. Stein, Jeffrey Y.C. Wong, Daniel A. Vallera, Joseph Rosenthal, Justin Molnar, Todd Ebner, Aaron Miller, Nicole Bowles, Kofi Poku, Junie Chea, Indu Nair, Paresh Vishwasrao, Marvin Orellana, Liliana Echavarria Parra, James Sanchez, Bijender Kumar, Darren Zuro, Jamison Brooks, Sargur Madabushi Srideshikan
Purpose:Acute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies (iliac crest). There is currently no AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c74f66efd63c5221603b7f6c19f9a8b
https://doi.org/10.1158/1078-0432.c.6528234
https://doi.org/10.1158/1078-0432.c.6528234
Autor:
Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Jeffrey Y.C. Wong, Lawrence E. Williams, Sanjiv S. Gambhir, Michael F. Press, Lin Li, Paul J. Yazaki, Desiree Crow, Anne-Line Anderson, Gobalakrishnan Sundaresan, Vania E. Kenanova, Tove Olafsen
Supporting Information from Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba7a2aa319b50dbb8084936e7d10390
https://doi.org/10.1158/0008-5472.22364756.v1
https://doi.org/10.1158/0008-5472.22364756.v1
Autor:
Jennifer Simpson, Ni-Chun Tsai, Diane Lynne Smith, John E. Shively, Firoozeh Sahebi, Dave Yamauchi, Joo Y. Song, Ricardo Spielberger, Vikram Adhikarla, Auayporn Nademanee, Sandra H. Thomas, Matthew Mei, David Colcher, Paul J. Yazaki, James R. Bading, S.V. Dandapani, Robert W. Chen, Alex F. Herrera, Pamela McTague, Erasmus Poku, Anna M. Wu, Thai Cao, Leslie Popplewell, Joycelynne Palmer, Eileen P. Smith, Nicole Karras, Stephen J. Forman, Jeffrey Y.C. Wong
Publikováno v:
Blood Advances. 5:5300-5311
High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with poor outcomes after conventional salvage therapy and autologous hematopoietic cell transplantation (AHCT). Post-AHCT consolidation with brentuximab vedotin (BV)
Autor:
Megan Minnix, Maciej Kujawski, Erasmus Poku, Paul J. Yazaki, Jeffrey Y. Wong, John E. Shively
Publikováno v:
J Nucl Med
Targeted α-therapy (TAT) delivers high-linear-transfer-energy α-particles to tumors with the potential to generate tumor immune responses that may be augmented by antigen-targeted immunotherapy. Methods: This concept was evaluated in immunocompeten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023046483158eb05680ff15033326e92
https://europepmc.org/articles/PMC9730924/
https://europepmc.org/articles/PMC9730924/
Autor:
Jeffrey Y C, Wong, David M, Yamauchi, Vikram, Adhikarla, Jennifer, Simpson, Paul H, Frankel, Yuman, Fong, Kurt A, Melstrom, Yi-Jen, Chen, Behrooz D, Salehian, Yanghee, Woo, Savita V, Dandapani, David M, Colcher, Erasmus K, Poku, Paul J, Yazaki, Anna M, Wu, John E, Shively
Publikováno v:
Cancer biotherapyradiopharmaceuticals.